Cost-effectiveness of implementing objective diagnostic verification of asthma in the United States
JournalJournal of Allergy and Clinical Immunology
MetadataShow full item record
AbstractBackground: Asthma diagnosis in the community is often made without objective testing. Objective: The aim of this study was to evaluate the cost-effectiveness of implementing a stepwise objective diagnostic verification algorithm among patients with community-diagnosed asthma in the United States. Methods: We developed a probabilistic time-in-state cohort model that compared a stepwise asthma verification algorithm on the basis of spirometry testing and a methacholine challenge test against the current standard of care over 20 years. Model input parameters were informed from the literature and with original data analyses when required. The target population was US adults (≥15 years old) with physician-diagnosed asthma. The final outcomes were costs (in 2018 dollars) and quality-adjusted life years (QALYs), discounted at 3% annually. Deterministic and probabilistic analyses were undertaken to examine the effect of alternative assumptions and uncertainty in model parameters on the results. Results: In a simulated cohort of 10,000 adults with diagnosed asthma, the stepwise algorithm resulted in removal of the diagnosis of 3,366. This was projected to be associated with savings of $36.26 million in direct costs and a gain of 4,049.28 QALYs over 20 years. Extrapolating these results to the US population indicated an undiscounted potential savings of $56.48 billion over 20 years. The results were robust against alternative assumptions and plausible changes in values of input parameters. Conclusion: Implementation of a simple diagnostic testing algorithm to verify asthma diagnosis might result in substantial savings and improvement in patients' quality of life. Copyright 2019 The Authors
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85078161533&doi=10.1016%2fj.jaci.2019.11.038&partnerID=40&md5=2f47c4d7f3c38a40d7a47e01019ebe6f; http://hdl.handle.net/10713/11661
- Development of an economic model to assess the cost effectiveness of asthma management strategies.
- Authors: Price MJ, Briggs AH
- Issue date: 2002
- COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.
- Authors: Ismaila AS, Risebrough N, Li C, Corriveau D, Hawkins N, FitzGerald JM, Su Z
- Issue date: 2014 Sep
- Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma.
- Authors: Zafari Z, Sadatsafavi M, Marra CA, Chen W, FitzGerald JM
- Issue date: 2016
- Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.
- Authors: Suzuki C, Lopes da Silva N, Kumar P, Pathak P, Ong SH
- Issue date: 2017 Aug
- A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma.
- Authors: Lam J, Hay JW, Salcedo J, Kenyon NJ
- Issue date: 2019 Aug